Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

VAD chemotherapy for refractory multiple myeloma.

H M Lokhorst1, O J Meuwissen, E J Bast

  • 1Department of Haematology, University Hospital, Utrecht, The Netherlands.

British Journal of Haematology
|January 1, 1989
PubMed
Summary

The VAD regimen (vincristine, adriamycin, and high-dose dexamethasone) showed a 50% complete remission rate in refractory multiple myeloma patients. Responders experienced improved quality of life and pain reduction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Leukemia·2017
Same author

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Leukemia·2017
Same author

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.

Bone marrow transplantation·2017
Same author

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.

Therapeutic advances in hematology·2016
Same author

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.

Clinical pharmacology and therapeutics·2016
Same author

Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.

Bone marrow transplantation·2016

Area of Science:

  • Hematology
  • Oncology
  • Clinical Pharmacology

Background:

  • Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
  • Refractory multiple myeloma poses a significant treatment challenge, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of the VAD regimen (vincristine, adriamycin, high-dose dexamethasone) in patients with refractory multiple myeloma.
  • To assess response rates, duration of response, survival, and prognostic factors associated with VAD therapy.

Main Methods:

  • A cohort of 34 patients with refractory multiple myeloma received 4-day continuous infusions of vincristine and adriamycin combined with 4-day pulsed high-dose dexamethasone (VAD).
  • Response was assessed in 31 evaluable patients, with analysis of remission duration, survival, performance status, and complications.

Related Experiment Videos

Main Results:

  • Sixteen of 31 evaluable patients (50%) achieved complete remission, and three (10%) achieved partial remission.
  • Median response duration was 9 months; median survival for responders was 12 months versus 4 months for non-responders.
  • High beta 2-microglobulin levels (≥4 µg/ml) were identified as a poor prognostic indicator.

Conclusions:

  • The VAD regimen demonstrates significant efficacy in refractory multiple myeloma, inducing complete remissions and improving patient quality of life.
  • Early consolidation therapy, such as high-dose melphalan, may be beneficial for patients with poor prognostic factors like high beta 2-microglobulin.
  • Bacterial infections were the primary complication, likely associated with the corticosteroid component of the VAD regimen.